UMass, U.K. Stem Cell Banks Sign Agreement As part of Governor Deval Patrick’s Innovation Economy Partnership Mission 2011, global leaders in the field of stem cell banking and characterization—the University of Massachusetts (UMass) Human Stem Cell Bank and Registry and the United Kingdom Stem Cell Bank—signed an agreement to share best practices for stem cell banking and to collaborate on standards for stem cell line characterization, production and distribution in the U.S. and U.K. [University of Massachusetts Medical School Press Release] Cellectis and the Etablissement Français du Sang Launch StemRed, a Program to Produce Red Blood Cells from Stem Cells Cellectis and Etablissement Français du Sang announce that StemRed, an ambitious collaborative program to produce red blood cells from induced pluripotent stem cells has started. [Cellectis Press Release] Seattle Genetics and Millennium Expand Antibody-Drug Conjugate Collaboration Seattle Genetics, Inc. announced that Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, has paid an undisclosed fee to exercise an option to designate a second antigen target under the parties’ existing antibody-drug conjugate collaboration. [Seattle Genetics, Inc. Press Release] Human Genome Sciences and Fiveprime Therapeutics Announce Development and Commercialization Agreement for Novel Anti-Cancer Drug Human Genome Sciences, Inc. and FivePrime Therapeutics, Inc. announced that they have entered into an agreement to develop and commercialize FivePrime’s FP-1039 product for multiple cancers. [FivePrime Therapeutics Inc. Press Release] Curis Announces Positive Results in Genentech Pivotal Phase II Clinical Trial of GDC-0449 in Advanced Basal Cell Carcinoma Curis, Inc. announced a positive outcome from a pivotal Phase II clinical trial conducted by Roche and Genentech, Curis’ collaborator and a wholly owned member of the Roche Group, of GDC-0449, a first-in-class hedgehog pathway inhibitor, in patients with advanced basal cell carcinoma. [Curis, Inc. Press Release] Pluristem Therapeutics and NYU Medical Center Partner to Study Use of PLX Cells in Treatment of Diabetic Foot Ulcers Pluristem Therapeutics, Inc. and New York University Medical Center announced the formation of a partnership to study the use of Pluristem’s proprietary placenta-derived PLX cells for the treatment of Diabetic Foot Ulcers. [Pluristem Therapeutics, Inc. Press Release] bluebird bio Awarded up to $4.2 Million from the French Muscular Dystrophy Association for Continued Development of Gene Therapy for Beta-Thalassemia and Sickle Cell Anemia bluebird bio announced that it has entered into an agreement with the French Muscular Dystrophy Association, a French non-profit entity, whereby the company will receive an initial amount of approximately $1.4 million in cash to support the development of LentiGlobin®, the company’s development-stage program for the treatment of beta-thalassemia and sickle cell anemia. [bluebird bio Press Release] Funding Boost for Synthetic Blood Research Work by researchers from the University of Glasgow who are developing synthetic human blood has been given a huge funding boost. The Scottish Funding Council are providing £2.5million over the next five years to help fund the work. [University of Glasgow Press Release] Federal Funding Enables CDRD’s Biologics Capabilities The Centre for Drug Research and Development (CDRD) and Western Economic Diversification Canada, announced $900,000 in Government of Canada support for the CDRD to establish a leading-edge Biologics Division at its research facilities located on the University of British Columbia campus. [Centre for Drug Research and Development Press Release] Important Funding for Nanomedicine Research to Improve Diagnosis and Treatment Seven new research projects on regenerative medicine and nanomedicine received $16 million in funding. [Canadian Institutes of Health Research Press Release] Oxford BioMedica Announces U.S. IND Approval for Novel Ocular Product in Stargardt Disease Oxford BioMedica plc announced that the U.S. Food and Drug Administration has approved its Investigational New Drug (IND) application for the Phase I/IIa clinical development of StarGen™, a novel gene-based treatment for Stargardt disease. [Oxford BioMedica plc Press Release] National Cord Blood Program Files Biologics License Application with FDA The National Cord Blood Program at New York Blood Center’s Howard P. Milstein National Cord Blood Center has submitted the first publicly-announced Biologics License Application for Cord Blood (Hematopoietic Progenitor Cells, Cord) to the Food and Drug Administration. [New York Blood Center Press Release] Genesis Biopharma Announces Plans to Develop Active Immunotherapy Platform Genesis Biopharma, Inc., a biotechnology company developing targeted cancer therapies, announced it is expanding its therapeutic strategy to include active immunotherapies to treat various cancers. [Genesis Biopharma, Inc. Press Release] University of Michigan Stem Cell Trial to Enter Crucial Phase The first clinical trial using stem cells in Lou Gehrig’s disease patients soon will begin testing the safety of the procedure in an area of the spine that eventually could be life-saving. [The Detroit News] RegeneRx Phase II AMI Trial on Clinical Hold Due to GMP Compliance Issues at Contract Manufacturer RegeneRx Biopharmaceuticals, Inc. announced that it has received a notice from the U.S. Food and Drug Administration (FDA) indicating that, due to non-compliance with FDA’s current Good Manufacturing Practice (GMP) regulations by its contract manufacturer, the Company’s Phase II clinical trial of RGN-352, its injectable formulation of Thymosin beta 4 for the treatment of acute myocardial infarction (AMI), has been placed on clinical hold. [RegeneRx Biopharmaceuticals, Inc. Press Release] bluebird bio Appoints World Leading Experts to Inaugural Scientific Advisory Board bluebird bio, an emerging leader in the development of innovative gene therapies for severe genetic disorders, announced the appointment of leading experts to its newly formed scientific advisory board. [bluebird bio Press Release] Seattle BioMed Announces Major Scientific Expansion, New Addition to Leadership In a bold plan for scientific expansion and leadership for the future, Seattle Biomedical Research Institute (Seattle BioMed) announced that it will integrate a systems biology approach with its global infectious disease research. [Seattle Biomedical Research Institute Press Release] Start-Up ImmusanT Seeks to Restore Tolerance to Gluten in Celiac Disease with Immunotherapy Biotechnology company ImmusanT, Inc. announced it has established its operations in Cambridge, Massachusetts and is advancing its strategy to develop an immunotherapeutic vaccine, companion diagnostic and monitoring tool for celiac disease. [PR Newswire] Laboratory for Malignancy Control Research Kyoto University and Dainippon Sumitomo Pharma Co., Ltd. announced the launch of a new cooperative project aiming at discovering innovative drugs, diagnostic tools, and therapeutic strategies for life-threatening cancers. [TherapeuticsDaily] Leaders in Stem Cell Research and Discovery to Share America’s Most Distinguished Prize in Medicine Three scientists whose pioneering work in isolating human stem cells holds great promise for the future of medicine have been named the recipients of the 11th annual Albany Medical Center Prize in Medicine and Biomedical Research. [PR Newswire] |